Literature DB >> 14506049

DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones.

C M Bébéar1, H Renaudin, A Charron, M Clerc, S Pereyre, C Bébéar.   

Abstract

Twelve clinical isolates of Ureaplasma spp. and one isolate of Mycoplasma hominis were examined for resistance to fluoroquinolones. Previously described mutations at positions 83 and 95 in GyrA (Escherichia coli numbering) and positions 80 and 87 in ParC were found. Unusual alterations were described at positions ParC 123 and 134.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14506049      PMCID： PMC201135          DOI： 10.1128/AAC.47.10.3323-3325.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Characterization of mutations in DNA gyrase and topoisomerase IV Involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro.

Authors:  A K Reinhardt; C M Bébéar; M Kobisch; I Kempf; A V Gautier-Bouchardon
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.

Authors:  C M Bebear; H Renaudin; A Charron; D Gruson; M Lefrancois; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.

Authors:  C M Bébéar; H Renaudin; A Charron; J M Bové; C Bébéar; J Renaudin
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.

Authors:  H Taba; N Kusano
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.

Authors:  C M Bebear; J Renaudin; A Charron; H Renaudin; B de Barbeyrac; T Schaeverbeke; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

6.  Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Species identification and subtyping of Ureaplasma parvum and Ureaplasma urealyticum using PCR-based assays.

Authors:  F Kong; Z Ma; G James; S Gordon; G L Gilbert
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

8.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

9.  Association of Ureaplasma urealyticum biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease.

Authors:  M Abele-Horn; C Wolff; P Dressel; F Pfaff; A Zimmermann
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

Review 10.  Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079
View more
  17 in total

1.  In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively.

Authors:  D Gruson; S Pereyre; H Renaudin; A Charron; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Ureaplasma urealyticum meningitis in an adult patient.

Authors:  Walter Geissdörfer; Günter Sandner; Stefan John; André Gessner; Christoph Schoerner; Klaus Schröppel
Journal:  J Clin Microbiol       Date:  2008-01-03       Impact factor: 5.948

3.  In vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan.

Authors:  Yasuhiro Kawai; Yukiko Nakura; Tetsu Wakimoto; Makoto Nomiyama; Tsugumichi Tokuda; Toshimitsu Takayanagi; Jun Shiraishi; Kenshi Wasada; Hiroyuki Kitajima; Tomio Fujita; Masahiro Nakayama; Nobuaki Mitsuda; Isao Nakanishi; Makoto Takeuchi; Itaru Yanagihara
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

4.  Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis.

Authors:  I Lysnyansky; I Mikula; I Gerchman; S Levisohn
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

5.  Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium.

Authors:  Kaitlin A Tagg; Neisha J Jeoffreys; Deborah L Couldwell; Jennifer A Donald; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

6.  Fluoroquinolone resistance in Ureaplasma parvum in the United States.

Authors:  Lynn Duffy; John Glass; Geraldine Hall; Robin Avery; Raymond Rackley; Scott Peterson; Ken Waites
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

7.  Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.

Authors:  Michael L Beeton; Victoria J Chalker; Nicola C Maxwell; Sailesh Kotecha; O Brad Spiller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

8.  In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.

Authors:  S Pereyre; H Renaudin; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum in asymptomatic women in Northern Greece.

Authors:  Tz Kotrotsiou; M Exindari; E Diza; G Gioula; A Melidou; K Kaplanis; N Malisiovas
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

10.  Antimicrobial Resistance in Clinical Ureaplasma spp. and Mycoplasma hominis and Structural Mechanisms Underlying Quinolone Resistance.

Authors:  Ting Yang; Lianlian Pan; Ningning Wu; Lin Wang; Zhen Liu; Yingying Kong; Zhi Ruan; Xinyou Xie; Jun Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.